Lichun Zhao | Cellular Senescence Aging | Best Researcher Award

Published on by Cell Biologist

Prof. Dr. Lichun Zhao | Cellular Senescence Aging | Best Researcher Award

Prof. Dr. Lichun Zhao | Guizhou University of Traditional Chinese Medicine | China

Dr. Lichun Zhao, Ph.D., is a distinguished researcher from Changchun, Jilin, China, currently a postdoctoral fellow at Hong Kong Baptist University and a leading academic at Guizhou University of Chinese Medicine. He serves as Director of both the Research Department and the Center for Trace Elements and Health Development. As the first National Youth Qihuang Scholar and winner of numerous prestigious awards, including the Guangxi Youth Science and Technology Award, Dr. Zhao has significantly advanced research in traditional Chinese medicine, trace elements, and mineral pharmacology. He holds editorial and leadership positions in several national academic and professional associations. With more than 200 publications. His work bridges science, technology, and healthcare innovation. Dr. Zhao remains a powerful force in scientific research and a mentor shaping the future of integrative medical sciences.

Publication Profile: 

Scopus

Education:

Dr. Lichun Zhao earned his Ph.D. from a top Chinese institution in a discipline closely linked to pharmaceutical sciences and traditional Chinese medicine (TCM). Building on his doctoral training, he advanced into postdoctoral research at Hong Kong Baptist University, a recognized hub for integrative medicine and health sciences. His academic foundation combines in-depth knowledge of biomedicine, trace elements, mineral nutrition, and traditional medicinal systems. This unique educational blend enabled him to pioneer multi-disciplinary research across TCM, pharmacology, and materials science. Dr. Zhao’s education journey reflects not only academic rigor but also his drive to merge traditional practices with modern science. His continuous learning through international collaborations, advanced certifications, and national talent programs demonstrates a lifelong commitment to scientific excellence and translational research. His education has played a pivotal role in forming his holistic, innovation-driven research vision that integrates ancient wisdom with contemporary health science.

Experience:

Dr. Zhao holds a multitude of roles showcasing his vast expertise. Currently, he is a postdoctoral fellow at Hong Kong Baptist University and a doctoral supervisor and director at Guizhou University of Chinese Medicine. He also serves as Director of Guizhou and Guangxi Key Laboratories focused on endangered medicinal materials. Additionally, he is the Executive Editor-in-Chief of Trace Elements and Health Research. Nationally recognized as a Qihuang Scholar, National Youth Post Expert, and leader in several elite Chinese talent development programs, he serves as an evaluator for China’s most prestigious science awards and grants. In his academic and professional trajectory, Dr. Zhao has hosted more than 30 major national and international research projects and contributed significantly to public health through innovative product development and clinical applications. His combined roles as researcher, leader, editor, mentor, and evaluator underscore his all-round impact in academic, industrial, and clinical ecosystems.

Research Focus:

Dr. Zhao’s research focuses on the biological roles and therapeutic potential of trace elements—notably Cu, Fe, Zn, Se, Rb, Cr, Si, and V—in relation to human health and chronic diseases, especially Alzheimer’s disease, cancer, ulcerative colitis, and chronic inflammatory conditions. He bridges Traditional Chinese Medicine (TCM) with modern bioscience, exploring minerals’ pharmacological effects, ferroptosis mechanisms, bacteriostatic mineral activity, and the integration of TCM with AI and big data. His innovative studies in MOF-polymer microreactors and rubidium salts demonstrate an advanced understanding of interfacial chemistry and drug delivery systems. He has developed Class 1.1 innovative Chinese medicine and contributed clinically approved products, highlighting his translational impact. His work also explores mitochondrial fission, apoptosis, and bioelement interactions at molecular and cellular levels. Dr. Zhao’s research philosophy is rooted in cross-disciplinary integration, with the goal of modernizing TCM and delivering tangible health benefits.

Publications Top Notes:

  1. The close relationship between trace elements (Cu, Fe, Zn, Se, Rb, Si, Cr, and V) and Alzheimer’s disease: Research progress and insights

  2. Bacteriostatic activity and mechanism of minerals containing rubidium – Science of Traditional Chinese Medicine

  3. Traditional Chinese medicine in chronic rhinosinusitis: Mechanisms and postoperative recovery – Phytomedicine

  4. Rosmarinic acid promotes mitochondrial fission and induces ferroptosis in triple-negative breast cancer cells – Naunyn Schmiedeberg’s Archives of Pharmacology

  5. Interfacial Stabilization through MOF-Polymer Core-Shell Design: Ultraefficient, Stable and Recyclable Enzymatic Microreactors – ACS Applied Materials & Interfaces

  6. Rubidium salt can effectively relieve the symptoms of DSS-induced ulcerative colitis – Biomedicine & Pharmacotherapy

Conclusion:

Dr. Lichun Zhao stands out as a multi-dimensional, high-impact researcher, blending scientific excellence, clinical innovation, technological advancement, and academic leadership. His contributions span traditional medicine, mineral pharmacology, chronic disease research, biotechnology, and national science development strategies. He embodies the vision of a modern, globally oriented researcher who successfully integrates traditional wisdom with contemporary science.

Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Published on by Cell Biologist

Dr. Jean-Marc LEMAITRE | Cellular Senescence Aging | Best Researcher Award

Dr. Jean-Marc LEMAITRE, INSERM UMR1183, France

Jean-Marc Lemaitre is a French biomedical researcher internationally renowned for his groundbreaking work on cellular reprogramming and aging reversal. Born on October 14, 1963, he is currently based at the Institute for Regenerative Medicine and Biotherapies (IRMB) in Montpellier, where he serves as co-director. His work has transformed the understanding of how aged cells can be rejuvenated, offering new hope for regenerative therapies. With a strong academic and clinical research background, Lemaitre has authored over 100 scientific articles and books on senescence, stem cells, and epigenetics. He is a board member of several scientific societies and journals, and continues to drive research at the frontier of aging science. Lemaitre is also a public science communicator and author, helping bridge cutting-edge biology with societal challenges related to aging. His passion for improving human health through innovative science places him at the forefront of biomedical research in France and globally.

Publication Profile:

Orcid

Google Scholar

Strengths for the Award:

  1. Pioneering Work in Aging Reversal
    Lemaitre was among the first scientists to show that senescent human cells can be rejuvenated, contributing significantly to cellular reprogramming and epigenetic longevity science.

  2. High-Impact Publications & Scientific Output
    Authored or co-authored over 100 scientific works, including in Nature Aging, Molecular Cell, Scientific Reports, and PNAS. His studies are cited globally in aging, regenerative medicine, and stem cell therapy.

  3. Institutional Leadership
    As Co-Director and Co-founder of IRMB, he manages a research institute with 180+ staff, positioning him as a key scientific leader in France.

  4. Scientific Recognition
    Member of scientific editorial boards and committees (e.g., Cells journal, Ligue Contre le Cancer), and board member of FSSCR, reflecting sustained leadership in the stem cell field.

  5. Translational & Interdisciplinary Impact
    His research has led to clinical insights in dermatology, osteoarthritis, and cardiology, demonstrating broad biomedical relevance beyond aging biology.

  6. Public Engagement and Science Communication
    Author of books like “Guérir la Vieillesse” and “Décider de son âge”, he bridges scientific knowledge with public interest in health and longevity.

Areas for Improvement:

  1. Expanded International Collaborations
    While Lemaitre collaborates across disciplines, further integration into global consortia or partnerships with biotech/pharma could amplify the translational value of his work.

  2. Visibility in Policy or Global Aging Initiatives
    Participation in policy advisory boards or international aging panels (e.g., WHO, UN Decade of Healthy Aging) would enhance his influence in shaping public health approaches to aging.

  3. Startups or Technology Transfer
    Commercialization of his discoveries (e.g., senescence therapies or reprogramming protocols) through startups or IP licensing would elevate his impact on innovation and real-world application.

Education:

Jean-Marc Lemaitre’s academic journey is rooted in molecular and developmental biology. He earned his DEA (Diplôme d’Études Approfondies) in Developmental Biology from Paris 6 University in 1991. His Doctorate (PhD) followed in 1995 from Paris 7 University, with research conducted at the esteemed Institut Jacques Monod in molecular and cellular biology. His early focus on the fundamental processes of cell development laid the groundwork for his future expertise in aging and regenerative medicine. In 2005, Lemaitre earned his Habilitation to Direct Research (HDR) from Montpellier University Medical School, a prestigious credential that allowed him to lead independent research projects. His educational path reflects a consistent and deep engagement with life sciences and a strong commitment to academic excellence. These milestones set the foundation for his leading role in cellular reprogramming and senescence-related research at both national and international levels.

Experience:

Jean-Marc Lemaitre has amassed over 30 years of professional experience in biomedical research, with a major focus on aging, senescence, and regenerative medicine. Since 2015, he has served as Co-Director and Cofounder of the IRMB (Institute for Regenerative Medicine and Biotherapies), which now houses over 180 researchers. His professional base is at the Saint Eloi Hospital in Montpellier, where he contributes both to translational research and clinical collaborations. Between 2014 and 2018, he held a Contrat d’Interface at CHU Montpellier, strengthening ties between research and healthcare. His pioneering work in cellular reprogramming earned international acclaim for demonstrating that senescent human cells could be rejuvenated using induced pluripotent stem cell (iPSC) technology. Lemaitre also plays leadership roles in research consortia such as the FHU REGENHAB and is an elected member of scientific committees, including the LIGUE Contre le Cancer du Septentrion. His experience is both deep and influential in shaping modern aging research.

Awards and Honors:

Jean-Marc Lemaitre has been recognized multiple times for his leadership and innovation in biomedical science. He was elected to the Scientific Committee of the LIGUE Contre le Cancer du Septentrion in 2019, reflecting his growing influence in translational medicine. In 2015, he co-founded and became Co-Director of IRMB, an institute now pivotal in stem cell and regenerative therapies. From 2014 to 2018, he was awarded a Contrat d’Interface at CHU Montpellier, enhancing integration between research and clinical practice. His work has also earned him positions on international editorial boards, including the “Cells” journal since 2020. In 2007, he co-founded and became a board member of the French Society for Stem Cell Research (FSSCR). These honors reflect not only the quality of his scientific contributions but also his dedication to mentorship, institution-building, and public engagement in science. He remains a key figure in aging and regenerative medicine globally.

Research Focus:

Jean-Marc Lemaitre’s research centers on cellular aging, senescence, and regenerative medicine. He is internationally renowned for demonstrating that aged or senescent human cells can be reprogrammed back to a pluripotent state—effectively reversing aging markers. His team has been at the forefront of identifying epigenetic mechanisms involved in aging and developing short reprogramming protocols to extend healthspan. He works extensively on senotherapeutics—interventions targeting the senescent cells that drive aging and disease—and has published seminal studies on skin aging, musculoskeletal regeneration, and systemic rejuvenation. Lemaitre is also a thought leader in developing blood-based epigenetic clocks to monitor aging and predict mortality. His integrative approach blends molecular biology, stem cell science, and translational medicine to uncover ways to slow or reverse aging processes. His work opens promising therapeutic avenues for treating age-related diseases, improving healthspan, and potentially redefining biological age through cellular reprogramming technologies.

Publications Top Notes:

  1. Disc-Derived iPSCs and Environmental Cues for Nucleus Pulposus Regeneration (Tissue Eng Part A, 2025)

  2. Blood-Based Epigenetic Clock for Intrinsic Capacity and Mortality (Nat Aging, 2025)

  3. Niacinamide and Hyaluronic Acid for Skin Aging: Clinical Correlation (Sci Rep, 2024)

  4. Décider de son âge (Book, 2024 – Allary Editions)

  5. Therapeutic Approaches Targeting Senescent Cells (Cells, 2023)

  6. Guérir la Vieillesse (Book, 2022 – Humensciences)

  7. Single Short Reprogramming Increases Healthspan (Aging, 2022)

  8. Epigenetic Mechanism Linking Early Reprogramming to Lifespan (Aging Cell, 2022)

  9. DNMT1-Driven 4D Genome Rewiring in Senescence (Molecular Cell, 2020)

  10. DNA Replication Timing as Marker in Progeroid Diseases (PNAS, 2017)

Conclusion:

Jean-Marc Lemaitre is a highly deserving candidate for the Best Researcher Award. He combines groundbreaking research in cellular aging and epigenetics with institutional leadership and public engagement. His work has transformed the understanding of biological aging, making him one of the most influential biomedical scientists in Europe in this domain. The award would not only recognize his scientific excellence but also highlight the increasing importance of healthy aging, regenerative medicine, and cellular rejuvenation in modern medicine.

Yizhong Peng | Cellular Senescence Aging | Best Researcher Award

Published on by Cell Biologist

Dr. Yizhong Peng | Cellular Senescence Aging | Best Researcher Award

Dr. Yizhong Peng , Wuhan Union Hospital , China

Dr. Peng Yizhong is an attending physician at Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, specializing in orthopedic spine and sports injuries. As a recipient of prestigious awards like the Postdoctoral Pioneer Talent Tracking Support Program and a Wuhan Talent, Dr. Peng has demonstrated exceptional contributions to both clinical practice and research. His work, supported by several grants from the National Natural Science Foundation of China, China Postdoctoral Science Foundation, and Hubei Province, highlights his expertise and commitment to advancing medical knowledge in orthopedics. With 30 published papers in leading journals, 15 granted patents, and significant contributions to the medical field, Dr. Peng is a recognized authority in his field. Additionally, he serves as a reviewer and editorial board member for high-impact journals.

Publication Profile:

Scopus

Strengths for the Award:

  1. Extensive Research Contribution: Dr. Peng has made significant contributions to orthopedic spine and sports injury research, with over 30 published papers in highly regarded journals such as Advanced Science, ACS Nano, Acta Pharmaceutica Sinica B, and Bioactive Materials. His publications reflect both a deep understanding and innovative approaches to addressing musculoskeletal disorders.

  2. Innovation and Patents: He has been granted 15 patents, including 2 international patents and 2 invention patents, showcasing his ability to translate research into practical, groundbreaking technologies in the field of orthopedics and regenerative medicine.

  3. Leadership in Research Projects: As the principal investigator for several major projects funded by prestigious bodies like the National Natural Science Foundation of China and China Postdoctoral Science Foundation, Dr. Peng has led key studies that contribute to the advancement of both clinical practices and technological innovations in orthopedic treatments.

  4. Academic Engagement: His role as an editorial board member for Biomaterials Translational and Exploration and a reviewer for high-impact journals highlights his prominence in the academic community. His collaborative nature further enhances his visibility and reputation among peers.

  5. Commitment to Patient Care: His dual focus on clinical applications and advanced research positions Dr. Peng as a well-rounded professional who not only generates knowledge but also translates it into impactful patient care.

Areas for Improvement:

  1. Broader Collaboration: While Dr. Peng has shown exceptional leadership in his specific research areas, broadening his collaborations with interdisciplinary teams or researchers from different regions could potentially expand his impact further, especially in global research environments.

  2. Public Engagement: Engaging more directly with the public, through outreach or educational initiatives, could help disseminate his findings and innovations to a broader audience, potentially benefiting more individuals affected by musculoskeletal conditions.

  3. International Recognition: Though Dr. Peng has made remarkable strides within China, increasing his presence and collaboration in international research conferences and publishing in global journals could help elevate his international recognition.

Education:

Dr. Peng Yizhong completed his education at prestigious institutions, where he earned his Ph.D. and postdoctoral degrees. His academic journey provided a strong foundation in both clinical medicine and research. He completed his postdoctoral research under the Postdoctoral Pioneer Talent Tracking Support Program, focusing on spine and sports injuries. This training equipped him with advanced research methodologies and an in-depth understanding of orthopedic diseases. Dr. Peng’s academic pursuits were further supported by his experience in various interdisciplinary fields, allowing him to approach complex medical problems with innovative solutions. His continuous learning, dedication, and commitment to advancing the field of orthopedics make him a prominent figure in both the academic and clinical research domains.

Experience:

Dr. Peng Yizhong has an extensive career spanning clinical and research roles in orthopedic medicine. As an attending physician at Union Hospital, Tongji Medical College, he specializes in treating spine and sports injuries, offering comprehensive care to patients. In parallel, his research focuses on novel treatment strategies and the development of advanced medical technologies. He has led numerous research projects funded by the National Natural Science Foundation of China, China Postdoctoral Science Foundation, and Hubei Province. His contributions to orthopedic medicine are further reflected in his active participation in international and national conferences, and his role as a young editorial board member of Biomaterials Translational and Exploration. With over 30 research publications and 15 patents, Dr. Peng has made groundbreaking advancements in his field, focusing on nanotechnology, regenerative medicine, and innovative treatment techniques. His interdisciplinary approach combines clinical practice with cutting-edge scientific research.

Research Focus:

Dr. Peng Yizhong’s research is centered on orthopedic spine injuries, sports-related injuries, and the application of advanced nanotechnology in medical treatments. His work explores innovative therapies, particularly in the context of orthopedic regeneration and healing. One of his major research areas involves studying the effects of dual-target nanotherapy, which aims to address steroid-induced osteonecrosis and enhance bone regeneration. Dr. Peng’s work also delves into regenerative medicine through the use of extracellular vesicles, stem cells, and novel drug delivery systems. His interdisciplinary approach is reflected in his exploration of bioactive materials, drug delivery mechanisms, and tissue engineering. Additionally, his research efforts in creating minimally invasive surgical techniques and improving arthroscopic methods have contributed to improved patient outcomes in orthopedic procedures. Through his commitment to both clinical and laboratory-based studies, Dr. Peng is advancing the understanding of complex musculoskeletal conditions and developing novel therapeutic approaches.

Publications Top Notes:

  1. Dual-target nanotherapy for vascular endothelium and bone mesenchymal stem cells halt steroid-induced osteonecrosis of the femoral head progression 🦴💉
  2. Arthroscopic 2-Portal Technique Using Percutaneous Spinal Needle Suture Passing With Suture Anchors for the Treatment of Calcific Insertional Achilles Tendinopathy 🦶🔩
  3. Arthroscopic Reduction and Transosseous Fixation of the Elbow Coronoid Process Fracture Using High-Strength Suture 💪💥
  4. Extracellular vesicles deliver thioredoxin to rescue stem cells from senescence and intervertebral disc degeneration via a feed-forward circuit of the NRF2/AP-1 composite pathway 🔬🧬
  5. A Simplified Technique for All-Inside Tibial Socket Retrograde Drill Guiding Using a 2- to 3.5-mm Concentric Cannula Without the All-Inside Tibial Guide Ring 🦵⚙️

Conclusion:

Dr. Peng Yizhong is undoubtedly a strong candidate for the Best Researcher Award due to his exceptional contributions to the field of orthopedic medicine. His innovative research, patent contributions, and leadership in funded projects, along with his clinical expertise, make him a standout researcher in his field. With further global collaboration and outreach, his impact on both the academic and clinical communities will continue to grow, making him a valuable asset to the medical research world.